Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab

Berman, Horacio; Rodríguez‐Pintó, Ignasi; Cervera, Ricard; Morel, Nathalie; Costédoat-Chalumeau, Nathalie; Erkan, Doruk; Shoenfeld, Yehuda; Espinosa, Gerard

doi:10.1016/j.autrev.2013.05.004

Cited by 222 publications

(130 citation statements)

References 21 publications

Supporting

Mentioning

114

Contrasting

Unclassified

Order By: Relevance

“…Two of the patients, who used rituximab as a first-line treatment, died. Rituximab was the second-line therapy in 12 patients (60%) who had poor response, relapsing episode, or worsening of clinical finding (2,7). In the present study patient, the reappearance of skin lesions postoperatively indicated the possibility of refractory CAPS; therefore, rituximab treatment was initiated.…”

Section: Discussionmentioning

confidence: 96%

Catastrophic antiphospholipid syndrome treated with rituximab: A case report

et al. 2017

View full text Add to dashboard Cite

Catastrophic antiphospholipid syndrome (CAPS) is a rare and fatal condition that is characterized by diffuse venous and/or arterial thromboembolism within a short period of time and histopathological confirmation of small-vessel occlusion in at least one organ or tissue in the presence of positive antiphospholipid antibodies. Here we report the case of a 19-year-old woman with CAPS. During the first week of her hospitalization, she was diagnosed with CAPS on the basis of skin necrosis, pulmonary artery thrombosis, cerebral venous sinus thrombosis, and positive lupus anticoagulant. She was treated with corticosteroids, intravenous immunoglobulins, plasmapheresis, and anticoagulants. Forty days after the onset of CAPS, cutaneous lesions were recurred during skin surgery. She required a high dose of corticosteroids, intravenous immunoglobulins, and rituximab. No further thrombotic events occurred. Rituximab may be an effective treatment option for patients with CAPS.

show abstract

Section: Discussionmentioning

confidence: 96%

Catastrophic antiphospholipid syndrome treated with rituximab: A case report

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Recientemente se han empleado anticuerpos monoclonales para el tratamiento del SAF catastrófico, pero la evidencia aún es escasa y solo hay reportes de casos anecdóticos. El rituximab fue empleado en 33 pacientes (6% de la serie) y el eculizumab en dos pacientes (0.2% de la serie) 12 . Se ha comunicado dos casos en los cuales se realizó prevención de la trombosis de injertos renales en pacientes con SAF catastrófico, con buen resultado; sin embargo, se recomienda realizar ensayos con mayor cantidad de pacientes.…”

Section: Figura 2 Datos De íLeo Líquido Libre Abdominal Y Neumatosiunclassified

“…En conclusión, el eculizumab podría implementarse como preventivo en los pacientes con SAF catastrófico que serán sometidos a trasplante renal y en aquellos en que las terapias convencionales han fallado para controlar la enfermedad, así como en cuadros recurrentes. Acorde a las conclusiones tomadas del International CAPS registry, el rituximab se recomienda para pacientes con SAF catastrófico refractario al tratamiento convencional [11][12][13][14][15] . Como resumen del tratamiento, todos los pacientes con SAF catastrófico deben ser tratados con anticoagulantes, esteroides y recambio plasmático/inmunoglobulina intravenosa.…”

Section: Figura 2 Datos De íLeo Líquido Libre Abdominal Y Neumatosiunclassified

Síndrome antifosfolípidos catastrófico. Reporte de caso y revisión bibliográfica

Carpio-Orantes

Martínez-Anaya

Bonilla-Casas

2017

GMM

View full text Add to dashboard Cite

“…Erre and co-workers described 12 patients with primary and SLE-associated APS who were treated with RTX [42]. RTX has also been shown to be an effective therapeutic option for life-threatening Catastrophic APS in a small number of patients [44]. B cells are likely to play a central role in the generation of the aPL-induced clinical manifestations of the disease, so could constitute a therapeutic target in APS.…”

Section: New Oral Anticoagulantsmentioning

confidence: 99%